Table 1.

Clinical characteristics of the study population. Continuous data are expressed as mean values ± standard deviation. The statistical comparison between the groups was carried out with the T-test or when reported (∗) with the Mann-Whitney test.

	AT	AT Controls	p value	Individuals with heterozygous mutation of ATM gene	Controls of individuals with heterozygous mutation of ATM gene	p value –
N.	27	27	–	29	29
Age (yy)	15.1 ± 7.6	14.6 ± 8.4	0.801	48.6 ± 8.4	49.9 ± 7.3	0.520
Gender (M/F)	13/14	13/14	1.0	10/19	10/19	1.0
BMI (Kg/m2)	16.6 ± 3.2	16.9 ± 2.7	0.772	25.7 ± 3.6	25.0 ± 2.8	0.431
Systolic BP (mmHg)	105 ± 8	106 ± 7	0.754	126 ± 20	121 ± 11	0.261
Diastolic BP (mmHg)	65 ± 8	66 ± 6	0.672	80 ± 10	79 ± 8	0.626
Total cholesterol mg/dl	137 ± 24	134 ± 28	0.677	130 ± 17	128 ± 21	0.709
Glycaemia (mg/dl)	85 ± 9	84 ± 8	0.715	90 ± 9	87 ± 7	0.201
Kidney failure	0	0	–	0	0	–
Hypertension	0	0	–	5	5	1.0
Previous Smoking	0	0	–	4	5	0.717
Hypercholesterolemia	2	0	0.150	2/29	2	1.0
Diabetes	1	0	0.313	0	0	–
Medications
Intra Erythrocyte Dexamethasone	7	0	<0.001	0	0	–
Intravenous or sub-cutaneous immunoglobulins	10	0	<0.001	0	0	–
Statins	1	0	0.313	0	0	–
Metformin	1	0	0.313	0	0	–
Antihypertensive drugs	0	0	–	4/29	5	0.716
Calcium oral intake	6	0	<0.001	0	0	–
Iron oral intake	2	0	0.150	0	0	–
N-Acetil-Cisteine	3	0	0.075	0	0	–
Carnitine	1	0	0.313	0	0	–
trimethoprim and sulphamethaoxazole	14	0	<0.001	0	0	–
FMD (%)	2.1 ± 3.1	8.5 ± 4.2	<0.001∗	4.6 ± 3.7	7.2 ± 2.5	0.003∗
NO bioavailability (μM)	10.5 ± 6.0	18.7 ± 5.2	<0.001∗	16.8 ± 3.6	20.8 ± 4.4	<0.001∗
sNOX2-dp (pg/ml)	29.1 ± 9.8	14.5 ± 3.6	<0.001	16.7 ± 5.5	12.2 ± 4.2	0.001
H2O2 (μM)	25.8 ± 8.6	14.8 ± 4.3	<0.001∗	15.9 ± 5.0	12.1 ± 4.2	0.01∗
HBA (%)	30.0 ± 11.0	43.6 ± 12.9	<0.001	41.0 ± 9.7	50.2 ± 13.5	<0.001
Occlusion Time (s)	349 ± 65	453 ± 42	<0.001∗	433 ± 77	488 ± 58	0.003
AUC (%)	366 ± 50	246 ± 48	<0.001	262 ± 70	210 ± 58	0.004